Artelo Biosciences Inc. (ARTL)
| Bid | 1.02 |
| Market Cap | 3.34M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -11.25M |
| EPS (ttm) | -2.87 |
| PE Ratio (ttm) | -0.36 |
| Forward PE | -2.48 |
| Analyst | Buy |
| Ask | 1.1 |
| Volume | 32,676 |
| Avg. Volume (20D) | 34,681 |
| Open | 1.00 |
| Previous Close | 1.00 |
| Day's Range | 1.00 - 1.04 |
| 52-Week Range | 0.91 - 1.70 |
| Beta | 1.06 |
About ARTL
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and ...
Analyst Forecast
According to 3 analyst ratings, the average rating for ARTL stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 479.71% from the latest price.
3 years ago · newsfilecorp.com
Artelo Biosciences to Present at the Q4 Investor Summit on November 17thSolana Beach, California--(Newsfile Corp. - November 11, 2021) - Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate endogenous signa...
